Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study. Circulation. 2000;102:2385 90. 347. Blackshear JL, Stambler BS, Strauss WE, et al. Control of heart rate dur- ing transition from intravenous to oral diltiazem in atrial fibrillation or flutter. Am J Cardiol. 1996;78:1246 50. 348. Singh BN, Hecht HS, Nademanee K, et al. Electrophysiologic and hemo- dynamic effects of slow-channel blocking drugs. Prog Cardiovasc Dis. 1982;25:103 32. 349. Akhtar M, Tchou P, Jazayeri M. Use of calcium channel entry blockers in the treatment of cardiac arrhythmias. Circulation. 1989;80:IV31 9. 350. Delle Karth G, Geppert A, Neunteufl T, et al. Amiodarone versus diltia- zem for rate control in critically ill patients with atrial tachyarrhythmias. Crit Care Med. 2001;29:1149 53. 351. Ellenbogen KA, Dias VC, Plumb VJ, et al. A placebo-controlled trial of continuous intravenous diltiazem infusion for 24-hour heart rate control during atrial fibrillation and atrial flutter: a multicenter study. J Am Coll Cardiol. 1991;18:891 7. 352. Ellenbogen KA, Dias VC, Cardello FP, et al. Safety and efficacy of in- travenous diltiazem in atrial fibrillation or atrial flutter. Am J Cardiol. 1995;75:45 9. 353. Platia EV, Michelson EL, Porterfield JK, et al. Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter. Am J Cardiol. 1989;63:925 9. 354. Salerno DM, Dias VC, Kleiger RE, et al. Efficacy and safety of intra- venous diltiazem for treatment of atrial fibrillation and atrial flutter. The Diltiazem-Atrial Fibrillation/Flutter Study Group. Am J Cardiol. 1989;63:1046 51. 355. Basta M, Klein GJ, Yee R, et al. Current role of pharmacologic therapy for patients with paroxysmal supraventricular tachycardia. Cardiol Clin. 1997;15:587 97. 356. Gallagher MM, Guo XH, Poloniecki JD, et al. 